Scimitar Equity Blog

OPXA reported a net loss of $1.29M or ($0.07) per share.  Read more…

OPXA’s  Q2/10 net loss was $1.82 M or ($0.12) per share. Read more…

OPXA to prepay the 10% Convertible Promissory Notes issued in April and May of 2009, which were originally issued as part of a bridge financing. The repayment of debt reduces interest payments and removes lien on assets. OPXA is delivering notice of this determination to the holders of the Notes, which is expected to result in a conversion to equity on the terms originally contemplated by the Notes, including at a conversion price of $0.50 per share. Read more…

Opexa reported a Q1/10 loss of $1.422 M, or ($0.09) per share. OPXA is developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS).  OPXA reported no revenues in Q1/10.  Read more…

Opexa Therapeutics reported (3/5/10)  a net loss of $1.43 M or $0.11 per diluted share for FY09 compared to $11.85 M or $1.12 per diluted share in FY08.  FY09 highlights:

• The pivotal point in the year was the completion of the stem cell transaction with Novartis (NVS) Pharmaceuticals for an upfront payment of $3 M and potential technology transfer milestone payments totaling another $1 M (with total potential payments from the deal that could exceed $50 M),

Read more…

Opexa Therapeutics develops of patient-specific cellular therapies for the treatment of autoimmune diseases. OPXA is developing Tovaxin®, an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin®  is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections triggering a potent immune response against specific subsets of autoreactive T-cells known to attack myelin, believed to be a primary cause of MS attacks and nervous system damage. Read more…

Opexa Therapeutics develops of patient-specific cellular therapies for the treatment of autoimmune diseases. Reiterating  from our 12/2/09 post – According to the National Multiple Sclerosis Society, MS affects approximately 2.5 M individuals worldwide. Industry experts estimated the global sales of MS therapeutics at approximately $6 B. Read more…

                        A new era in embryonic stem cell research is evolving as the NIH approved 13 batches Read more…

Opexa Therapeutics, Inc. is develops of patient-specific cellular therapies for the treatment of autoimmune diseases.  Market Opportunity: The name Multiple Sclerosis (MS) simply refers to the buildup of scar tissue in the brain and spinal cord. An unpredictable disease of the central nervous system, multiple sclerosis can range from being relatively benign to somewhat disabling to devastating as communication between the brain and other parts of the body is disrupted. Read more…